{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:22:24Z","timestamp":1787829744624,"version":"build-2784847793"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis and high relapse rates when treated with cytotoxic chemotherapeutics. Previously, we identified a family of small molecules that modulate mitochondrial function, referred to as PS127-family compounds. These drugs were selectively toxic to AML and were characterized by two predicted functions: apoptotic agonism and thioredoxin\/glutathione reductase inhibition. Here, we uncovered a third critical predicted function, autophagic induction. Using a cheminformatic screen of ~4.2 million compounds for molecules with high predicted probability for all three functions, we found and validated hits that selectively killed AML cells, activated apoptosis, were dependent upon autophagic activation, and compromised glutathione metabolism by interfering with glutathione reductase, all of which are consistent with predictions. Compound treatment increased pools of cytosolic and mitochondrial ROS, decreased oxygen consumption, and reduced ATP synthesis. Structurally unrelated compounds caused the same phenotypes, validating our approach of screening for predicted function. Finally, we also observed strong synergy between these compounds and midostaurin and venetoclax, underscoring their therapeutic potential. Key phenotypes, including the compounds\u2019 impact on glutathione metabolism and synergy with doxorubicin and midostaurin, were confirmed in AML-patient-derived primary cells, validating the potential of these compounds for the development of future AML treatments.<\/jats:p>","DOI":"10.1038\/s41375-026-03104-z","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:14:58Z","timestamp":1787822098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cheminformatic identification of small molecules targeting acute myeloid leukemia"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6649-9631","authenticated-orcid":false,"given":"Megan R.","family":"Daneman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadetta","family":"Meika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Armendariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6577-0757","authenticated-orcid":false,"given":"Elissa","family":"Tjahjono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Revtovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid A.","family":"Stolbov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-403X","authenticated-orcid":false,"given":"Natthakan","family":"Thongon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-5693","authenticated-orcid":false,"given":"Scott R.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7937-2621","authenticated-orcid":false,"given":"Vladimir V.","family":"Poroikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-4967","authenticated-orcid":false,"given":"Natalia V.","family":"Kirienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"3104_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102549","volume":"71","author":"MS Linet","year":"2024","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019. eClinicalMedicine. 2024;71:102549.","journal-title":"eClinicalMedicine"},{"key":"3104_CR2","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3390\/cells9102310","volume":"9","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020;9:2310.","journal-title":"Cells"},{"key":"3104_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/bjh.18613","volume":"200","author":"A Frisch","year":"2023","unstructured":"Frisch A, Rowe JM, Ofran Y. The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia. Br J Haematol. 2023;200:556\u201362.","journal-title":"Br J Haematol"},{"key":"3104_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40170-021-00253-w","volume":"9","author":"SB Panina","year":"2021","unstructured":"Panina SB, Pei J, Kirienko NV. Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer Metab. 2021;9:17.","journal-title":"Cancer Metab"},{"key":"3104_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrd2137","volume":"8","author":"BBS Zhou","year":"2009","unstructured":"Zhou BBS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8:806\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"3104_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341.","journal-title":"Cell Stem Cell"},{"key":"3104_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.807266","volume":"12","author":"Y Mesbahi","year":"2022","unstructured":"Mesbahi Y, Trahair TN, Lock RB, Connerty P. Exploring the metabolic landscape of AML: from haematopoietic stem cells to myeloblasts and leukaemic stem cells. Front Oncol. 2022;12:807266.","journal-title":"Front Oncol"},{"key":"3104_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1532857","volume":"14","author":"E Tjahjono","year":"2025","unstructured":"Tjahjono E, Daneman MR, Meika B, Revtovich AV, Kirienko NV. Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia. Front Oncol. 2025;14:1532857.","journal-title":"Front Oncol"},{"key":"3104_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1244280","volume":"13","author":"L Feng","year":"2023","unstructured":"Feng L, Zhang PY, Gao W, Yu J, Robson SC. Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia. Front Oncol. 2023;13:1244280.","journal-title":"Front Oncol"},{"key":"3104_CR10","doi-asserted-by":"publisher","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","volume":"288","author":"S Pei","year":"2013","unstructured":"Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem. 2013;288:33542\u201358.","journal-title":"J Biol Chem"},{"key":"3104_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, et al. Mubritinib targets the electron transport chain complex i and reveals the landscape of oxphos dependency in acute myeloid leukemia. Cancer Cell. 2019;36:84\u201399.e8.","journal-title":"Cancer Cell"},{"key":"3104_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41375-022-01614-0","volume":"36","author":"SB Panina","year":"2022","unstructured":"Panina SB, Pei J, Baran N, Tjahjono E, Patel S, Alatrash G, et al. Novel mitochondria-targeting compounds selectively kill human leukemia cells. Leukemia. 2022;36:2009\u201321.","journal-title":"Leukemia"},{"key":"3104_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889875","volume":"13","author":"M Romo-Gonz\u00e1lez","year":"2022","unstructured":"Romo-Gonz\u00e1lez M, Ijurko C, Hern\u00e1ndez-Hern\u00e1ndez \u00c1. Reactive oxygen species and metabolism in leukemia: a dangerous liaison. Front Immunol. 2022;13:889875.","journal-title":"Front Immunol"},{"key":"3104_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102814","volume":"144","author":"K Mattes","year":"2019","unstructured":"Mattes K, Vellenga E, Schepers H. Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: a potential window for leukemia therapy. Crit Rev Oncol Hematol. 2019;144:102814.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3104_CR15","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood-2016-04-708750","volume":"128","author":"M Dany","year":"2016","unstructured":"Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016;128:1944\u201358.","journal-title":"Blood"},{"key":"3104_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood-2019-127024","volume":"134","author":"HRS Fay","year":"2019","unstructured":"Fay HRS, Dykstra KM, Johnson M, Cronin TL, Lutgen-Dunckley L, Martens BL, et al. Mitophagy plays a key role in the anti-leukemic activity of autophagy inhibitors under hypoxia in acute myeloid leukemia. Blood. 2019;134:1278\u20131278.","journal-title":"Blood"},{"key":"3104_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1182\/bloodadvances.2020002666","volume":"5","author":"KM Dykstra","year":"2021","unstructured":"Dykstra KM, Fay HRS, Massey AC, Yang N, Johnson M, Portwood S, et al. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv. 2021;5:2087\u20132100.","journal-title":"Blood Adv"},{"key":"3104_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1194\/jlr.M067389","volume":"57","author":"SAF Morad","year":"2016","unstructured":"Morad SAF, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, et al. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia1. J Lipid Res. 2016;57:1231\u201342.","journal-title":"J Lipid Res"},{"key":"3104_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","volume":"13","author":"C Glytsou","year":"2023","unstructured":"Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, et al. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov. 2023;13:1656\u201377.","journal-title":"Cancer Discov"},{"key":"3104_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fonc.2020.00435","volume":"10","author":"SB Panina","year":"2020","unstructured":"Panina SB, Pei J, Baran N, Konopleva M, Kirienko NV. Utilizing synergistic potential of mitochondria-targeting drugs for leukemia therapy. Front Oncol. 2020;10:435.","journal-title":"Front Oncol"},{"key":"3104_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97148-z","volume":"11","author":"E Tjahjono","year":"2021","unstructured":"Tjahjono E, Pei J, Revtovich AV, Liu TJE, Swadi A, Hancu MC, et al. Mitochondria-affecting small molecules ameliorate proteostasis defects associated with neurodegenerative diseases. Sci Rep. 2021;11:17733.","journal-title":"Sci Rep"},{"key":"3104_CR22","first-page":"747","volume":"16","author":"A Lagunin","year":"2000","unstructured":"Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: prediction of activity spectra for biologically active. substances Bioinforma Oxf Engl. 2000;16:747\u20138.","journal-title":"substances Bioinforma Oxf Engl"},{"key":"3104_CR23","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gkr320","volume":"39","author":"TWH Backman","year":"2011","unstructured":"Backman TWH, Cao Y, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39:W486\u2013491.","journal-title":"Nucleic Acids Res"},{"key":"3104_CR24","doi-asserted-by":"crossref","unstructured":"Pei J, Panina SB, Kirienko NV. An automated differential nuclear staining assay for accurate determination of mitocan cytotoxicity. J Vis Exp JoVE. 2020;10:3791\/61295.","DOI":"10.3791\/61295-v"},{"key":"3104_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s10593-014-1496-1","volume":"50","author":"DA Filimonov","year":"2014","unstructured":"Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, et al. Prediction of the biological activity spectra of organic compounds using the pass online web resource. Chem Heterocycl Compd. 2014;50:444\u201357.","journal-title":"Chem Heterocycl Compd"},{"key":"3104_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1851-3","volume":"10","author":"SB Panina","year":"2019","unstructured":"Panina SB, Baran N, Brasil Da Costa FH, Konopleva M, Kirienko NV. A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs. Cell Death Dis. 2019;10:617.","journal-title":"Cell Death Dis"},{"key":"3104_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-018-0059-z","volume":"15","author":"A Picca","year":"2018","unstructured":"Picca A, Mankowski RT, Burman JL, Donisi L, Kim JS, Marzetti E, et al. Mitochondrial quality control mechanisms as molecular targets in cardiac ageing. Nat Rev Cardiol. 2018;15:543\u201354.","journal-title":"Nat Rev Cardiol"},{"key":"3104_CR28","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u2013W493.","journal-title":"Nucleic Acids Res"},{"key":"3104_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol OncolJ Hematol Oncol. 2021;14:49.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"3104_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3892\/ijo.2020.5052","volume":"57","author":"M Vu","year":"2020","unstructured":"Vu M, Kassouf N, Ofili R, Lund T, Bell C, Appiah S. Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl-2 in acute myeloid leukaemia MOLM-13 cells with reduced Beclin 1 expression. Int J Oncol. 2020;57:113\u201321.","journal-title":"Int J Oncol"},{"key":"3104_CR31","volume":"16","author":"HA Sherif","year":"2021","unstructured":"Sherif HA, Magdy A, Elshesheni HA, Ramadan SM, Rashed RA. Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia. Leuk Res Rep. 2021;16:100272.","journal-title":"Leuk Res Rep"},{"key":"3104_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"3104_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/2040620717721459","volume":"8","author":"MM Gallogly","year":"2017","unstructured":"Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol. 2017;8:245\u201361.","journal-title":"Ther Adv Hematol"},{"key":"3104_CR34","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1111\/jcmm.14927","volume":"24","author":"E Weisberg","year":"2020","unstructured":"Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, et al. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020;24:2968\u201380.","journal-title":"J Cell Mol Med"},{"key":"3104_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1515\/tjb-2021-0152","volume":"47","author":"HN \u015eahin","year":"2022","unstructured":"\u015eahin HN, Adan A. Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild-type acute myeloid leukemia cells. Turk J Biochem. 2022;47:49\u201358.","journal-title":"Turk J Biochem"},{"key":"3104_CR36","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. Ca. 2025;75:46\u201367.","journal-title":"Ca"},{"key":"3104_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1476-5381.2012.02110.x","volume":"168","author":"BL Heckmann","year":"2013","unstructured":"Heckmann BL, Yang X, Zhang X, Liu J. The autophagic inhibitor 3-methyladenine potently stimulates PKA-dependent lipolysis in adipocytes. Br J Pharmacol. 2013;168:163\u201371.","journal-title":"Br J Pharmacol"},{"key":"3104_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3892\/ol.2014.1879","volume":"7","author":"Q Liu","year":"2014","unstructured":"Liu Q, Luo XY, Jiang H, Yang MH, Yuan GH, Tang Z, et al. Hydroxychloroquine facilitates autophagosome formation but not degradation to suppress the proliferation of cervical cancer SiHa cells. Oncol Lett. 2014;7:1057\u201362.","journal-title":"Oncol Lett"},{"key":"3104_CR39","doi-asserted-by":"publisher","first-page":"10850","DOI":"10.1074\/jbc.M109.080796","volume":"285","author":"YT Wu","year":"2010","unstructured":"Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 2010;285:10850\u201361.","journal-title":"J Biol Chem"},{"key":"3104_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1104\/pp.110.167569","volume":"155","author":"CH Foyer","year":"2011","unstructured":"Foyer CH, Noctor G. Ascorbate and glutathione: the heart of the redox Hub1. Plant Physiol. 2011;155:2\u201318.","journal-title":"Plant Physiol"},{"key":"3104_CR41","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1093\/jxb\/erae023","volume":"75","author":"CH Foyer","year":"2024","unstructured":"Foyer CH, Kunert K. The ascorbate\u2013glutathione cycle coming of age. J Exp Bot. 2024;75:2682\u201399.","journal-title":"J Exp Bot"},{"key":"3104_CR42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/antiox11101993","volume":"11","author":"A G\u0119gotek","year":"2022","unstructured":"G\u0119gotek A, Skrzydlewska E. Antioxidative and anti-inflammatory activity of ascorbic acid. Antioxidants. 2022;11:1993.","journal-title":"Antioxidants"},{"key":"3104_CR43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/10715760210873","volume":"36","author":"H Masaki","year":"2002","unstructured":"Masaki H, Okano Y, Ochiai Y, Obayashi K, Akamatsu H, Sakurai H. alpha-tocopherol increases the intracellular glutathione level in HaCaT keratinocytes. Free Radic Res. 2002;36:705\u20139.","journal-title":"Free Radic Res"},{"key":"3104_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.brainres.2005.06.030","volume":"1052","author":"KI Siler-Marsiglio","year":"2005","unstructured":"Siler-Marsiglio KI, Pan Q, Paiva M, Madorsky I, Khurana NC, Heaton MB. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res. 2005;1052:202\u201311.","journal-title":"Brain Res"},{"key":"3104_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1749-6632.1987.tb23761.x","volume":"498","author":"E Niki","year":"1987","unstructured":"Niki E. Interaction of ascorbate and alpha-tocopherol. Ann N Y Acad Sci. 1987;498:186\u201399.","journal-title":"Ann N Y Acad Sci"},{"key":"3104_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fphar.2014.00151","volume":"5","author":"V Ribas","year":"2014","unstructured":"Ribas V, Garc\u00eda-Ruiz C, Fern\u00e1ndez-Checa JC. Glutathione and mitochondria. Front Pharmacol. 2014;5:151.","journal-title":"Front Pharmacol"},{"key":"3104_CR47","doi-asserted-by":"publisher","unstructured":"Vivoli M, Novak HR, Littlechild JA, Harmer NJ. Determination of protein-ligand interactions using differential scanning fluorimetry. J Vis Exp JoVE. 2014;51809. https:\/\/doi.org\/10.3791\/51809.","DOI":"10.3791\/51809"},{"key":"3104_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tiv.2017.04.028","volume":"42","author":"LF de Souza","year":"2017","unstructured":"de Souza LF, Schmitz AE, da Silva LCS, de Oliveira KA, Nedel CB, Tasca CI, et al. Inhibition of reductase systems by 2-AAPA modulates peroxiredoxin oxidation and mitochondrial function in A172 glioblastoma cells. Toxicol Vitr. 2017;42:273\u201380.","journal-title":"Toxicol Vitr"},{"key":"3104_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63104","volume":"10","author":"MA Nelson","year":"2021","unstructured":"Nelson MA, McLaughlin KL, Hagen JT, Coalson HS, Schmidt C, Kassai M, et al. Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia. eLife. 2021;10:e63104.","journal-title":"eLife"},{"key":"3104_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899502","volume":"12","author":"M Peng","year":"2022","unstructured":"Peng M, Huang Y, Zhang L, Zhao X, Hou Y. Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells. Front Oncol. 2022;12:899502.","journal-title":"Front Oncol"},{"key":"3104_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.seminoncol.2008.04.003","volume":"35","author":"WI Chan","year":"2008","unstructured":"Chan WI, Huntly BJP. Leukemia stem cells in acute myeloid leukemia. Semin Oncol. 2008;35:326\u201335.","journal-title":"Semin Oncol"},{"key":"3104_CR52","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","volume":"30","author":"X Du","year":"2007","unstructured":"Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30:607.","journal-title":"J Immunother"},{"key":"3104_CR53","doi-asserted-by":"publisher","first-page":"34056","DOI":"10.18632\/oncotarget.26118","volume":"9","author":"AM Zahran","year":"2018","unstructured":"Zahran AM, Aly SS, Rayan A, El-Badawy O, Fattah MA, Ali AM, et al. Survival outcomes of CD34+CD38\u2212LSCs and their expression of CD123 in adult AML patients. Oncotarget. 2018;9:34056\u201365.","journal-title":"Oncotarget"},{"key":"3104_CR54","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1080\/07391102.2021.1932598","volume":"40","author":"VK Vyas","year":"2022","unstructured":"Vyas VK, Bhati S, Patel S, Ghate M. Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwards. J Biomol Struct Dyn. 2022;40:10481\u2013506.","journal-title":"J Biomol Struct Dyn"},{"key":"3104_CR55","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"SY Yang","year":"2010","unstructured":"Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010;15:444\u201350.","journal-title":"Drug Discov Today"},{"key":"3104_CR56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","volume":"93","author":"JM Paggi","year":"2024","unstructured":"Paggi JM, Pandit A, Dror RO. The art and science of molecular docking. Annu Rev Biochem. 2024;93:389\u2013410.","journal-title":"Annu Rev Biochem"},{"key":"3104_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-62703-023-6_16","volume":"914","author":"S Vilar","year":"2012","unstructured":"Vilar S, Costanzi S. Predicting biological activities through QSAR analysis and docking-based scoring. Methods Mol Biol Clifton Nj. 2012;914:271\u201384.","journal-title":"Methods Mol Biol Clifton Nj"},{"key":"3104_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-024-03934-7","volume":"14","author":"NS Dutra","year":"2024","unstructured":"Dutra NS, da Silva D\u2019\u00c1vila CM, da Silva TC, de Oliveira Mendes T, Livinalli IC, Bertoncelli ACZ, et al. Biological properties of caffeine, (+)-catechin, and theobromine: an in silico study. 3 Biotech. 2024;14:94.","journal-title":"3 Biotech"},{"key":"3104_CR59","doi-asserted-by":"crossref","unstructured":"Fatima I, Rehman A, Wang P, He Z, Liao M. Discovery of small molecule inhibitors targeting CTNNB1 (\u03b2-catenin) for endometrial cancer: employing 3D QSAR, drug-likeness assessment, ADMET predictions, molecular docking and simulation. Curr Med Chem. 2026;33:1383\u2013404.","DOI":"10.2174\/0109298673307257240826111754"},{"key":"3104_CR60","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.3389\/fmicb.2018.03317","volume":"9","author":"DR Kirienko","year":"2019","unstructured":"Kirienko DR, Kang D, Kirienko NV. Novel pyoverdine inhibitors mitigate pseudomonas aeruginosa pathogenesis. Front Microbiol. 2019;9:3317.","journal-title":"Front Microbiol"},{"key":"3104_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29039-4","volume":"13","author":"R Anderson","year":"2022","unstructured":"Anderson R, Miller LD, Isom S, Chou JW, Pladna KM, Schramm NJ, et al. Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nat Commun. 2022;13:1673.","journal-title":"Nat Commun"},{"key":"3104_CR62","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37:1277\u201384.","journal-title":"J Clin Oncol"},{"key":"3104_CR63","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145:1237\u201350.","journal-title":"Blood"},{"key":"3104_CR64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s11658-024-00613-6","volume":"29","author":"P Auberger","year":"2024","unstructured":"Auberger P, Favreau C, Savy C, Jacquel A, Robert G. Emerging role of glutathione peroxidase 4 in myeloid cell lineage development and acute myeloid leukemia. Cell Mol Biol Lett. 2024;29:98","journal-title":"Cell Mol Biol Lett"},{"key":"3104_CR65","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-18-3223","volume":"25","author":"MA Gregory","year":"2019","unstructured":"Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res. 2019;25:4079\u201390.","journal-title":"Clin Cancer Res"},{"key":"3104_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102692","volume":"62","author":"RGA Costa","year":"2023","unstructured":"Costa RGA, Silva SLR, Dias IRSB, Oliveira M, De S, Rodrigues ACB, Da C, Dias RB, et al. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biol. 2023;62:102692.","journal-title":"Redox Biol"},{"key":"3104_CR67","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111:312\u201322.","journal-title":"Cancer Sci"},{"key":"3104_CR68","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/ijms23031912","volume":"23","author":"BB Wu","year":"2022","unstructured":"Wu BB, Leung KT, Poon ENY. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022;23:1912.","journal-title":"Int J Mol Sci"},{"key":"3104_CR69","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788\u2013801.","journal-title":"Cancer"},{"key":"3104_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905.","journal-title":"Blood Rev"},{"key":"3104_CR71","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/blood-2015-05-646497","volume":"127","author":"C Larrue","year":"2016","unstructured":"Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127:882\u201392.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03104-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:03:21Z","timestamp":1787828601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03104-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":71,"alternative-id":["3104"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03104-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study includes de-identified patient samples provided by MD Anderson Cancer Center Leukemia Sample Bank. This research was determined to be non-human subjects research by Rice University\u2019s Institutional Review Board.","order":2,"name":"Ethics","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE","group":{"name":"EthicsHeading","label":"Ethics"}}]}}